Drug intelligence / Profile preview

CAR19-T Cell Engager

Development stage
Preclinical
Lead developer
Aleta Biotherapeutics
Modality
T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration
Intravenous
01

Overview

CAR19-T Cell Engager is an engineered biologic protein designed to enhance the anti-tumor activity of CAR19 T cells against solid tumors. This multi-antigen targeting engager protein binds simultaneously to tumor antigens, specifically IL13Rα2 and B7-H3, present on cancer cells. Concurrently, it engages and activates CD19-CAR T cells via its CD19 extracellular domain, while also providing crucial costimulatory signals through incorporated CD58 binding domains. The construct is further armored with a monomeric TGFβR2 protein, which is intended to counteract tumor-mediated immunosuppression and improve T cell survival, proliferation, and differentiation, thereby amplifying the therapeutic efficacy of CAR19 T cells.

Other names
CAR19-TECAR-19-TECAR 19-TE
02

Targets

CD19 (B lymphocyte antigen CD19)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on CAR19-T Cell Engager.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAR19-T Cell Engager.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call